KEGG   DRUG: Pegcetacoplan
Entry
D11613                      Drug                                   
Name
Pegcetacoplan (JAN/USAN/INN);
Empaveli (TN)
Formula
C170H248N50O47S4. (C2H4O)n
Remark
ATC code: L04AA54
Efficacy
Complement inhibitor
  Disease
Paroxysmal nocturnal hemoglobinuria [DS:H01053]
Comment
Treatment of paroxysmal nocturnal hemoglobinuria (PNH), complement-mediated nephropathies, and age-related macular degeneration (AMD)
Target
C3 (C3b) [HSA:718] [KO:K03990]
  Pathway
hsa04610  Complement and coagulation cascades
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L04 IMMUNOSUPPRESSANTS
   L04A IMMUNOSUPPRESSANTS
    L04AA Selective immunosuppressants
     L04AA54 Pegcetacoplan
      D11613  Pegcetacoplan (JAN/USAN/INN)
USP drug classification [BR:br08302]
 Immunological Agents
  Immunological Agents, Other
   Complement Inhibitors
    Pegcetacoplan
     D11613  Pegcetacoplan (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
 Not elsewhere classified
  Organismal systems
   Complement and coagulation
    C3 (C3b)
     D11613  Pegcetacoplan (JAN/USAN/INN)
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11613
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11613
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11613
Other DBs
CAS: 2019171-69-6
PubChem: 405226480
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system